Lercapin

Quick links to important sections

Lercapin

Method of action: Antihypertensive, Hypotensive

Treatment option: Hypertension

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lercapin

Property Description
Active Ingredient Lercanidipine hydrochloride
Form Film-Coated Tablets
Pharmacological Class Antihypertensive, Dihydropyridine Calcium Channel Blocker (CCB)
General Purpose Reduction of high blood pressure
Origin Synthetic molecule (chemically synthesized)

What is Lercapin and Its Core Composition?

Lercapin is a prescription-only, single-substance medication presented for oral administration as a Film-Coated Tablet. Its pharmaceutical identity is centered on the active component, Lercanidipine hydrochloride, a synthetic small molecule specifically manufactured for therapeutic use. Lercanidipine is chemically defined as a highly lipophilic dihydropyridine derivative, a property that is significant in its mechanism of action.

Lercapin's Classification as an Antihypertensive

Lercapin belongs to the primary drug class of Antihypertensives, designated for the therapeutic reduction of high arterial pressure. Its specific functional category is a Calcium Channel Blocker (CCB) of the Dihydropyridine type. Supporting clinical data confirm that Lercanidipine is a third-generation CCB, characterized by its high degree of vascular selectivity. This high selectivity is a differentiating factor, assuring that the drug’s primary effect is focused on widening blood vessels rather than significantly affecting myocardial function.

What is the General Purpose of Lercanidipine?

The fundamental purpose of Lercanidipine is to provide sustained management of elevated blood pressure. It achieves this by modulating calcium flow into the smooth muscle cells lining the arterial walls, resulting in the relaxation and widening of the blood vessels, known as peripheral vasodilation. This physiological effect effectively lowers the total peripheral resistance in the circulatory system, which is the core mechanism for controlling chronic high blood pressure.

What side effects are possible with Lercapin?

The official safety documentation for Lercanidipine classifies potential side effects based on their frequency of occurrence, primarily related to the medication's blood-vessel widening properties. These effects are grouped by the affected System-Organ-Class (SOC) as listed by regulatory authorities.

Documented Adverse Reactions

Common adverse reactions (may affect up to 1 in 10 people) are typically vascular and neurological, including headache, dizziness, and flushing. Other common effects are palpitations, tachycardia, and peripheral oedema. Regulatory data notes that these common reactions are often transient and may resolve during continued treatment.

Uncommon adverse reactions (may affect up to 1 in 100 people) include hypotension (low blood pressure), somnolence, fatigue, and gastrointestinal symptoms such as nausea and dyspepsia.

Safety Constraints and Serious Events

Serious adverse events are also documented, although their frequency may be classified as Not Known (cannot be estimated). These include the risk of myocardial infarction and severe dermatological reactions such as Stevens-Johnson Syndrome (SJS). For individuals with pre-existing angina pectoris, an increase in the frequency or severity of angina may occur, particularly at the beginning of treatment.

Specific Contraindications are defined in official labeling. Lercapin is restricted in individuals with severe hepatic impairment or severe renal impairment (creatinine clearance less than 30 ml/min). The medication is also contraindicated during pregnancy and lactation. Furthermore, co-administration with substances like Grapefruit juice and strong CYP3A4 inhibitors is explicitly contraindicated due to enhanced safety risks.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Lercanidipine (Lercapin) describes overdose as an extreme exaggeration of its pharmacological effects on the cardiovascular system.

Documented Clinical Manifestations: Overdosage may result in excessive peripheral vasodilation, leading to severe hypotension (dangerously low blood pressure) and reflex tachycardia (rapid heart rate). Further severe manifestations documented include bradycardia (slow heart rate), somnolence, and potentially unconsciousness. Patients with pre-existing angina pectoris may experience an increase in the frequency or duration of chest pain.

Required Emergency Actions: It is formally mandated that in the event of a suspected Lercanidipine overdose, immediate medical attention must be sought. Due to the potential for prolonged and life-threatening cardiovascular effects, hospital monitoring is required for at least 24 hours.

Management Notes: Regulatory guidance states that no specific antidote is known. Treatment is symptomatic and supportive. Procedures mentioned in official documents include the use of gastric lavage and activated charcoal to help limit drug absorption. The high protein binding of Lercanidipine means standard procedures like dialysis are expected to be ineffective.

Therapeutic Uses of Lercapin

Lercapin is commonly used in situations involving the management of high blood pressure (Hypertension), and its therapeutic benefit generally supports long-term disease modification. The medication is primarily used for managing Essential Hypertension, a condition marked by persistently elevated arterial pressure. This treatment is generally considered relevant for mild and moderate pressure elevations and may be part of symptomatic management for severe cases.

The primary focus is on the management of the condition itself. The medication provides support that generally helps in addressing elevated blood pressure readings, which assists with maintaining general well-being during symptomatic periods. A key long-term benefit of using Lercapin to help manage hypertension may assist with managing the long-term risk of developing serious vascular episodes, and contributes to easing the overall risk associated with cardiovascular and cerebrovascular events. It is also considered relevant for patient groups with Type 2 Diabetes Mellitus, where it supports a beneficial effect and is considered relevant for supporting kidney function.

“This medication supports a key, long-term strategy aimed at easing the overall risk of serious vascular episodes.”


Quick Fact: Relief for Elevated Arterial Pressure Lercapin is generally applied in addressing the systemic imbalance caused by persistently high blood pressure, and contributes to easing the overall symptom load during periods of noticeable strain.

Eligibility and Restrictions for Use

Lercapin (Lercanidipine) is approved for use in adults aged 18 years and over for the treatment of mild to moderate essential hypertension. The medication is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established in the pediatric population.

Regulatory documents explicitly list multiple conditions that contraindicate the use of Lercapin:

  • Cardiovascular: Untreated congestive cardiac failure, left ventricular outflow tract obstruction, unstable angina pectoris, or having had a myocardial infarction within the last one month.
  • Organ Impairment: Severe hepatic impairment or severe renal impairment (GFR < 30 mL/min), including patients undergoing dialysis.
  • Reproductive Status: The drug is not recommended during pregnancy or lactation. It is contraindicated in women of child-bearing potential unless effective contraception is used.
  • Co-administration: Use is contraindicated with strong CYP3A4 inhibitors (such as ketoconazole), ciclosporin, or grapefruit/grapefruit juice.

Treatment initiation requires special care in older adults and in patients with mild to moderate renal or hepatic dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Lercanidipine's interaction profile predominantly through its dependency on the CYP3A4 metabolic pathway.

Interaction Classifications and Restrictions

Classification Interacting Substance or Product
Contraindicated Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin), Cyclosporin (Ciclosporin)
Prohibited Food Grapefruit or Grapefruit Juice
Requires Caution CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine), High-dose Cimetidine, Alcohol

Co-administration with strong CYP3A4 inhibitors is strictly prohibited because these substances cause a marked increase in Lercanidipine plasma levels. Similarly, the use of Cyclosporin is contraindicated due to a documented increase in the drug's systemic exposure. Grapefruit juice must not be consumed as it inhibits Lercanidipine's metabolism, enhancing its effect. Concomitant use with other antihypertensives, such as beta-blockers (e.g., Metoprolol), may reduce Lercanidipine bioavailability. Lercanidipine also affects the disposition of other medicines, specifically increasing the maximum plasma concentration ( C max) of Digoxin.

Timing and Population-Specific Notes

The official label states that to manage absorption, Lercanidipine must be taken at least 15 minutes before breakfast. The antihypertensive effect may be enhanced in patients with moderate hepatic impairment.

Mechanism of Action

Specific Blockade of L-type Calcium Channels

Lercapin functions as a selective inhibitor by binding to and blocking the L-type Voltage-Gated Calcium Channels (CaV1.2) primarily located on the membranes of vascular smooth muscle cells. By impeding the influx of extracellular calcium ions ( Ca^2+), the drug interrupts the necessary molecular signal required for the initiation of muscle contraction.


Regulation of Vascular Tone and Systemic Resistance

This calcium channel blockade initiates a mechanistic cascade resulting in the relaxation of the arterial smooth muscle, a process known as peripheral vasodilation. This action causes a reduction in the Total Peripheral Resistance (TPR) to blood flow throughout the circulatory system, which is the primary physiological consequence achieved by this mechanism.


⏳ Sustained Action through Membrane Selectivity

The molecule's high lipophilicity allows it to reside within the cell membrane (a membrane depot effect), enabling a prolonged and gradual interaction with the calcium channels. This specialized mechanism facilitates the maintenance of the physiological state of reduced vascular resistance over a prolonged duration. This high vascular selectivity results in a mechanism that preferentially targets peripheral channels, distinguishing it from mechanisms that exert more direct influence on myocardial contractility.

Dosage and Administration Information

Lercapin is administered exclusively through the oral route as a film-coated tablet, available in both 10 mg and 20 mg strengths. The established regimen is to take the medication once daily, preferably in the morning. The typical starting dose for adults is 10 mg, with the maintenance dose ranging from 10 mg to a maximum recommended dose of 20 mg per day. Dose adjustments are not made immediately; rather, an increase from 10 mg to 20 mg should be considered gradual, allowing approximately two weeks for the maximal antihypertensive effect to develop before any titration is finalized.

A critical instruction for proper use involves the timing of administration relative to food. Lercapin must be taken at least 15 minutes before a meal to ensure consistent absorption and maximum availability. Furthermore, the medication must not be taken with grapefruit juice. The tablet should be swallowed whole with water, and the score line present on some tablets is designed only to facilitate swallowing, not to divide the tablet into equal doses. Special care and cautious dose adjustments are noted for use in older adults and patients with mild to moderate kidney or liver impairment. Use in the pediatric population is not recommended, as safety and efficacy have not been established.

Recent Clinical Evidence

Lercapin: Recent Clinical Evidence

Evidence for Use in Essential Hypertension

The core research for Lercapin was studied in adults with high blood pressure, known as Essential Hypertension. The most established evidence comes from Randomized Controlled Trials (RCTs) where Lercapin was evaluated in trials involving placebo and other established blood pressure medications as comparators. These trials primarily research examined changes in Systolic and Diastolic Blood Pressure (SBP/DBP) and monitored how many patients' readings aligned with predetermined target levels over defined time intervals. Studies reported measurements of SBP and DBP change and described the proportion of participants whose measurements reached research thresholds. Comparative studies also monitored measurements of blood pressure variability over 24 hours.

Evidence in Special Populations and Long-Term Data

Dedicated research also examined specific patient groups, including those with Type 2 Diabetes Mellitus and elderly patients (aged 60 and over), often focusing on Isolated Systolic Hypertension (ISH) in older adults. The available evidence includes both short-term efficacy trials (4 to 12 weeks) and longer-term observational studies that track patterns related to the duration of the blood pressure changes over periods up to a year or two. Research describes that short-term changes appear to persist for the follow-up duration of these studies.

What is Still Uncertain About Lercapin Research

The primary limitation is that research has overwhelmingly focused on surrogate endpoints, specifically blood pressure change. There is limited information for long-term outcomes, as large-scale studies that track hard clinical events like stroke, heart attack, or mortality over many years are not fully established. Furthermore, data for certain groups remain insufficient to fully characterize long-term patterns for all individuals with complex, co-existing health conditions.

Key Studies & References

  1. Lercanidipine in hypertension (Used for general efficacy, special populations, and long-term activity profile)
  2. Lercanidipine hydrochloride 10 mg Film-coated Tablets - Summary of Product Characteristics (Used for regulatory context, special populations, and contraindication context)
  3. Public Assessment Report - Lercanidipine HCl Mylan 10 mg and 20 mg (Used for non-linear pharmacokinetics and elimination context)
  4. Lercanidipine hydrochloride - Australian Prescriber (Used for short-term study findings and lack of long-term data context)

Frequently Asked Questions (FAQ)

Common questions about Lercapin (FAQ)


Q: How quickly should I expect to see my blood pressure go down after starting Lercapin?

According to official product information, the effect is gradual. It may take approximately two weeks for the maximal antihypertensive effect to be fully apparent, which guides decisions regarding dosage changes.


Q: What happens if I miss a dose of Lercapin—do I need to take it right away?

Official patient information notes that if a dose is missed but remembered within 12 hours of the usual time, it may be taken then. If more than 12 hours have passed, that day's dose should be skipped, and the next dose is typically continued as scheduled the following day.


Q: Is it better to take Lercapin in the morning or at night?

Regulatory documents indicate that Lercapin should be taken once daily, and it is generally recommended to take the tablet in the morning.


Q: Do I need to take Lercapin with food, or can I take it on an empty stomach?

To ensure proper absorption, official guidance states that Lercapin must be taken on an empty stomach. The tablet should be taken at least 15 minutes before any meal, such as before breakfast.


Q: If Lercapin is working, can I eventually stop taking it?

Lercapin is generally prescribed as a long-term treatment to control high blood pressure, not to cure the underlying condition. The medication is typically continued for as long as prescribed by a healthcare provider.


Q: Does Lercapin interact with over-the-counter pain relievers like ibuprofen?

Specific over-the-counter pain relievers like ibuprofen are not mentioned in the main drug label. However, it is noted that caution should be exercised with any medication that also lowers blood pressure, as the combination could potentially increase the risk of side effects like dizziness or fainting.


Q: Can Lercapin be taken at the same time as cholesterol-lowering medicines (statins)?

Lercapin uses the same metabolic pathway (CYP3A4) as certain statins. While often prescribed together, monitoring may be performed by a healthcare professional due to this shared metabolic route, although no general contraindication is stated.


Q: Can Lercapin affect a person's mood or cause depression?

Official safety data lists somnolence (drowsiness) as an uncommon reaction, and anxiety or insomnia have been rarely reported. Depression or specific mood disorders are not listed among the common or uncommon reported side effects.


Q: Does Lercapin affect male fertility or sexual function?

Impotence (erectile dysfunction) has been reported as an uncommon adverse reaction in regulatory safety documentation for Lercapin.


Q: Does Lercapin interact with common cold or flu medications?

Common cold or flu medicines are not specifically listed in the drug interaction information. However, caution should be exercised when combining Lercapin with any product that might also lower blood pressure.


Q: Does Lercapin have a long half-life, meaning it stays in the system for a while?

The drug is highly lipid soluble, which allows it to reside longer in the cell membrane (a membrane depot effect). This prolonged interaction leads to a sustained, 24-hour effect, despite a short elimination time from the bloodstream.


Q: How is Lercapin different from other calcium channel blockers?

Lercapin is a third-generation dihydropyridine calcium channel blocker. It has high vascular selectivity, meaning its primary effect is focused on relaxing blood vessel walls rather than significantly affecting the heart muscle.


Q: Can Lercapin be used to treat high blood pressure caused by stress?

Lercapin is formally indicated only for the treatment of mild to moderate essential hypertension (high blood pressure with no known cause). The regulatory indication does not specifically extend to high blood pressure caused by stress.


Q: Is Lercapin commonly prescribed for people with isolated systolic hypertension?

The regulatory indication is for essential hypertension in adults. However, clinical studies have specifically evaluated the use of Lercapin in elderly patients diagnosed with Isolated Systolic Hypertension (ISH).


Q: How long is a typical course of treatment with Lercapin?

Treatment for essential hypertension is typically long-term, requiring the medication to be taken daily. It should be continued for as long as advised by the prescribing doctor.


Q: Does Lercapin cause fatigue or tiredness, and does that go away?

Fatigue and somnolence (sleepiness) are reported as possible side effects. These reactions are generally noted in safety reports to be mild to moderate in intensity.


Q: Can Lercapin affect blood sugar levels in people without diabetes?

Official safety data indicates that Lercapin is not known to have adverse effects on blood sugar or lipid (fat) levels in patients without diabetes.


Q: Are there any herbal supplements or vitamins that should be avoided with Lercapin?

The drug label offers little specific information regarding herbal supplements or vitamins. Patients are generally advised to inform their healthcare provider or pharmacist about all supplements they are taking to check for potential risks.


Q: Can men use Lercapin, or is it mainly for women?

Lercapin is indicated for use in all adults aged 18 and over for essential hypertension. There are specific warnings regarding use in women of child-bearing potential, but no gender restrictions for men.


Q: Is it okay to drink alcohol in moderation while on Lercapin?

Official patient information advises that alcohol should be avoided or restricted. This is because alcohol may potentiate (increase the effect of) the vasodilating properties of the medication.


Q: What are the signs that Lercapin might be causing a serious allergic reaction?

Patients should monitor for signs of Hypersensitivity (listed as very rare) or severe allergic reactions, such as Angioedema (swelling in the deeper layers of the skin or throat), which may signal a need for medical review.


Q: If I switch from another blood pressure medicine to Lercapin, what should I look out for?

When Lercapin is added to or replaces an existing antihypertensive drug, the patient's blood pressure should typically be monitored more frequently than usual during the adjustment period.


Q: Can Lercapin cause insomnia or affect sleep patterns?

Insomnia, meaning difficulty sleeping, is listed as a rare adverse event in the regulatory safety documentation for Lercapin.


Q: What kind of monitoring (blood tests) is needed when taking Lercapin?

Official data reports isolated and reversible increases in hepatic transaminases (liver enzymes). This suggests that monitoring of liver enzyme levels may be needed during the course of treatment.


Q: Is Lercapin safe to use for people who have liver problems?

Lercapin is strictly contraindicated (not allowed) in patients with severe hepatic (liver) impairment. Caution and careful monitoring are required for patients with mild to moderate liver impairment.


Q: Are there generic versions of Lercapin available, and are they the same?

Lercanidipine is the generic name of the active ingredient and is available under various brand names, such as Zanidip. Generic versions contain the same active ingredient and work in the same way.


Q: What is the research evidence showing Lercapin's effectiveness?

Clinical studies have shown Lercapin to be effective in reducing systolic and diastolic blood pressure. A high proportion of patients in clinical trials reached target blood pressure levels within weeks of beginning monotherapy.


Q: Has Lercapin been studied in people with diabetes and high blood pressure?

Yes, dedicated clinical studies have evaluated the safety and effectiveness of Lercapin specifically in patients who have both Type 2 Diabetes Mellitus and mild to moderate hypertension.


Q: Why do some doctors prescribe Lercapin as a second-line treatment?

Lercapin is approved for use as initial monotherapy but is also proven to be effective in combination with other classes of antihypertensive drugs. This suggests flexibility in its application across multiple lines of therapy.


Q: Is Lercapin approved for treating any conditions other than high blood pressure?

The sole approved regulatory indication for Lercapin is for the treatment of mild to moderate essential hypertension. It is not approved for any other conditions.


Q: What should I do if my blood pressure still seems high after taking Lercapin for a week?

The official product information indicates that the full blood pressure-lowering effect may take about two weeks to appear. Therefore, dose adjustments are typically not considered until after this initial two-week period.


Q: Is it safe to drive or operate machinery after taking Lercapin?

Side effects such as dizziness, somnolence (sleepiness), and fatigue may occur while taking this medication. The ability to drive or operate machinery may be impaired if these effects are experienced.


Q: What are the long-term safety data for Lercapin?

Available research has largely focused on surrogate endpoints, measuring changes in blood pressure itself. There is limited published information on hard, long-term clinical outcomes such as stroke or mortality.


Q: If I am taking Lercapin, are there any dietary changes I should make?

The most critical dietary instruction is the strict avoidance of grapefruit and grapefruit juice, as they are prohibited due to the risk of serious interaction. No other specific food is strictly contraindicated.


Q: Is Lercapin safe to use if I have a history of heart failure?

Lercapin is strictly contraindicated in patients with untreated congestive cardiac failure. The medication requires caution in patients with left ventricular dysfunction.


Q: Can Lercapin be taken by people who are sensitive to lactose?

The medication contains lactose. Individuals with rare hereditary problems, such as galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption, is not recommended for individuals with these conditions.


Q: What does 'selective calcium channel blocker' mean in the context of Lercapin?

The term selective means the drug has a high degree of preference for certain tissues. Lercapin preferentially targets the calcium channels in the blood vessel walls to cause vasodilation, rather than strongly affecting the heart muscle.

How should Lercapin be stored and disposed of?

How to Store and Dispose of Lercapin?

Lercapin (lercanidipine hydrochloride) must be stored and disposed of strictly according to its official regulatory labeling to maintain quality and ensure environmental safety.

Storage Requirements

Condition Requirement
Temperature Do not store above 25 C (77°F).
Protection Store in the original package to protect from moisture and light.
Child Safety Must be kept out of the sight and reach of children.
Stability Do not use after the expiry date printed on the carton.

Disposal Instructions

To dispose of unused or expired Lercapin, the product must not be thrown away via wastewater or household waste. Patients are required to ask a pharmacist for guidance on proper disposal, which must be in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lercapin found in:

A-Z Index: